Name | PX-12 |
Synonyms | PX-12 PX 12 IV-2) CS-2384 PX-12 (PX12 2-(sec-Butyldisulfanyl)-1H-iMidazole 2-[(1-Methylpropyl)dithio]-1H-imidazole 1H-Imidazole, 2-[(1-methylpropyl)dithio]- |
CAS | 141400-58-0 |
Molecular Formula | C7H12N2S2 |
Molar Mass | 188.31 |
Density | 1.19±0.1 g/cm3(Predicted) |
Boling Point | 330.0±25.0 °C(Predicted) |
Solubility | DMSO: ≥ 44.7 mg/mL |
Appearance | powder |
Color | off-white to tan |
pKa | 11.88±0.10(Predicted) |
Storage Condition | 2-8°C |
In vitro study | In MCF-7 and HT-29 cells, PX-12 prevented the HIF-1alpha protein increase induced by hypoxia (1% oxygen) and decreased HIF-1 transactivation activity, VEGF formation, and inducible nitric oxide synthase. PX-12 also inhibited the growth of MCF-7 and HT-29 cells, with IC50s of 1.9 μm and 2.9 μm, respectively. PX-12 also inhibits HIF-1α protein levels through an increase mediated by Nrf2/PMF-1. In A549 cells, PX-12 inhibited cell growth by G2/M cell cycle arrest, and Bax-mediated, ROS-dependent apoptosis. In liver cancer cells, PX-12 and 5-FU play a synergistic effect, significantly inhibit Tumorigenicity. |
In vivo study | PX-12 (12 mg/kg, I. p.) decreased HIF-1α and VEGF protein levels and microvessel density in mice bearing MCF-7 tumor xenografts. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
HS Code | 29332900 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 5.31 ml | 26.551 ml | 53.103 ml |
5 mM | 1.062 ml | 5.31 ml | 10.621 ml |
10 mM | 0.531 ml | 2.655 ml | 5.31 ml |
5 mM | 0.106 ml | 0.531 ml | 1.062 ml |